|
from SABCS
I heard it too this was a finnish study all part of a trend towards a cost benefit analysis.....my thought was that I would love to see this reproduced. There were also questions on the selection critieria of the cohorts. BUT, if it does pan-out, what a boost to the global medical economies who can't afford 1 year of treatment. Also, I think this was with node negative patients??
Al
__________________
Primary care-giver to and advocate for Linda, who passed away April 27, 2006.
|